| James Joseph Simons, MD | |
|
999 6th St, Traverse City, MI 49684-2301 | |
| (231) 941-4114 | |
| (231) 941-0878 |
| Full Name | James Joseph Simons |
|---|---|
| Gender | Male |
| Speciality | Dermatology - Procedural Dermatology |
| Location | 999 6th St, Traverse City, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982766465 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207NS0135X | Dermatology - Procedural Dermatology | 4301039948 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| James Joseph Simons, MD 999 6th St, Traverse City, MI 49684-2301 Ph: (231) 941-4114 | James Joseph Simons, MD 999 6th St, Traverse City, MI 49684-2301 Ph: (231) 941-4114 |
News Archive
Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis.
Speaking this week at "the 99th Indian Science Congress, the country's largest annual gathering of scientists," Prime Minister Manmohan Singh "said the occasion demanded looking anew at the role of science in a country 'grappling with the challenges of poverty and development'" and "emphasized that 'the overriding objective of a comprehensive and well-considered policy for science, technology and innovation should be to support the national objective of faster, sustainable and inclusive development,'" SciDev.Net reports.
The study began with the generation of recombinant (r)SA11 rotaviruses, into which segment 7 modified RNAs were introduced. These encoded sequences for the non-structural protein NSP3 and some parts of the viral spike.
Novartis today announced full results from the positive Phase III PARADIGMS study, investigating the safety and efficacy of Gilenya (fingolimod) vs. interferon beta-1a, in children and adolescents (ages 10 to 17) with multiple sclerosis (MS).
WHAT: In a finding that could soon help people infected with untreatable, highly drug-resistant tuberculosis (TB), scientists have shown that two FDA-approved drugs work in tandem to kill laboratory-grown strains of Mycobacterium tuberculosis (Mtb), the bacterium that causes TB.
› Verified 4 days ago
Raymond J Dean, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3643 W Front St Ste A, Traverse City, MI 49684 Phone: 231-935-0620 Fax: 231-935-0626 | |
Paula L Cahill, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 550 Munson Ave, Suite 200, Traverse City, MI 49686 Phone: 231-935-8717 Fax: 231-935-9230 | |
Maria C Carroll, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 550 Munson Ave, Suite 200, Traverse City, MI 49686 Phone: 231-935-8717 Fax: 231-935-9230 | |
Joan M Griner Licht, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3643 W Front St Ste A, Traverse City, MI 49684 Phone: 231-935-0620 Fax: 231-935-0626 | |
Dr. Jeffrey John Kelly, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3643 W Front St, Suite A, Traverse City, MI 49684 Phone: 231-935-0620 Fax: 231-935-0626 | |
Susan C Noble, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 550 Munson Avenue, Suite 200, Traverse City, MI 49686 Phone: 231-935-8717 Fax: 231-935-9230 | |
Anthony C Vanvreede, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1225 W Front St Ste C, Traverse City, MI 49684 Phone: 231-642-5031 Fax: 231-525-2306 |